Citations

Clear

2429 citation(s) found for "Shah, SS".

Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression
Gupta, Sounak, Kosari, Farhad , Thapa, Prabin , Murphy, Stephen J, Johnson, Sarah H. , Dashti, Nooshin K. , Tekin, Burak, Dasari, Surendra, Kipp, Benjamin R. , Sharma, Vidit, Shah, Paras H, Orme, Jacob J. , Frank, Igor, Karnes, R Jeffrey, Boorjian, Stephen A, Vasmatzis, George , Cheville, John C, Zarka, Jabra G, Orme, Jacob J , Murphy, Stephen J. , Greipp, Patricia T. , Tekin, Burak , Zarka, Jabra , Sharma, Vidit , Shah, Paras H., Frank, Igor, Karnes, R. Jeffrey, Boorjian, Stephen A. , Cheville, John C.

Mayo Clinic

Am J Clin Pathol | February 26, 2026 | Volume: 165 | Issue: 4 | Pages: No page available

10.1093/ajcp/aqag023 | PMID 41969028 Get It

Abstract Objectives Sarcomatoid urothelial carcinoma (sUC) is associated with poor clinical outcomes. Herein, we evaluated clinicopathologic features (including PD-L1 expression) for institutional cases. Methods Sixty-five patients with sUC treated by radical cystectomy were matched for age, sex, and pathologic stage to 190 patients with pure urothelial carcinoma (UC). Outcomes were evaluated using the Kaplan-Meier method. Immunohistochemistry (IHC) results for tumor-specific PD-L1 expression in sUC were quantified using H-scores (range, 0-300). Cases with constitutive PD-L1 expression (cPD-L1; H-score ≥240) were evaluated for amplification events using fluorescence in situ hybridization (n = 28), mate-pair sequencing (Mpseq; n = 6), RNA sequencing (n = 5), and targeted next-generation sequencing (n = 8). PD-L1 regulatory pathways were evaluated using gene set enrichment analysis in the Cancer Hallmark dataset. Results Most patients with sUC had advanced disease (≥pT2, 62/65, 95%), without significant differences in overall and cancer-specific survival, when matched to pure UC. Median PD-L1 H-scores using different clones were 100 (SP142), 120 (SP263), and 195 (22C3). cPD-L1 was seen in 43% (28/65) of cases of sUC that were enriched for TP53, TERT, and CDKN2A/B alterations. PD-L1 amplification was identified in 7 (of 28, 25%) of these cases. Bionformatics analysis consistently identified IL6-JAK-STAT3 and interferon α/γ signaling in sUC with cPD-L1 expression. Conclusions Our results suggest that cPD-L1 expression in most sUC occurs secondary to IL6-JAK-STAT3 and interferon α/γ signaling. This provides a biologic rationale for evaluating response to immunotherapy in this patient population.
VEGF Inhibitors in Hematologic Cancers and Hypertension/Cardiac Effects
Thukral, Jatin, Kaur, Harbir, Sindhwani, Ninaad, Moudgil, Pyush, Chandani, Kanishka Uttam, Shah, Riya Kaushal, Thukral, Nikhil, Agrawal, Siddharth , Frishman, William H., Aronow, Wilbert S., Thukral, Jatin, Kaur, Harbir, Thukral, Nikhil, Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | February 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001219 | PMID 41738812 Get It

The therapeutic landscape of hematologic malignancies has undergone a paradigm shift with the increasing incorporation of targeted therapies, including inhibitors of vascular endothelial growth factor (VEGF) signaling. While VEGF-directed agents have historically been developed and deployed in solid tumors, their application in hematologic cancers—particularly multiple myeloma, select leukemias, and rare lymphomas—has expanded in investigational and clinical settings. VEGF is fundamental to angiogenesis, maintenance of endothelial integrity, and regulation of vascular tone. As a result, therapeutic inhibition of VEGF signaling is associated with a characteristic spectrum of cardiovascular adverse effects. These include hypertension, endothelial dysfunction, heart failure, thromboembolic complications, and renal injury, all of which present important clinical challenges in patients with hematologic malignancies. This population frequently has additional vulnerability due to factors such as cytopenias, preexisting renal impairment, and prior exposure to cardiotoxic anticancer therapies. This review aims to provide a cardio-oncology–oriented overview of VEGF biology, the range of VEGF-targeted agents used in hematologic cancers, and the underlying mechanisms driving their cardiovascular toxicities.
DinoAtten3D: Slice-Level Attention Aggregation of DinoV2 for 3D Brain MRI Anomaly Classification
Rafsani, Fazle , Wu, Teresa S., Shah, Jay , Chong, Catherine D. , Schwedt, Todd J.

Mayo Clinic

2025 IEEE/CVF International Conference on Computer Vision Workshops (ICCVW) | February 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: 3594-3603

10.1109/iccvw69036.2025.00375 Get It

Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Shah, Nishant , Peterson, Eric D. , Shrader, Peter, Shoji, Satoshi , Freeman, Nikki , Martin, Seth S., Allred, Clint, Fernandez, S. A., Chamberlain, Alanna M., Arnold, Jonathan , Shapiro, Michael D., Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Kalich, Bethany , Jin, Ran , Navar, Ann Marie, Peterson, Eric D. , Chamberlain, Alanna M. , Arnold, Jonathan , Shah, Nishant P , Martin, Seth S , Fernandez, Soledad , Chamberlain, Alanna M , Shapiro, Michael D , Effron, Mark B , Syed, Mahanaz , Kirchner, H Lester , Kalich, Bethany , Jin, Ran , Wojcik, Cezary , Navar, Ann Marie , Shrader, Peter, Martin, Seth S. , Ahmad, Zahid , Jones, Laney K , Návar, Ann Marie

Mayo Clinic

Circulation: Population Health and Outcomes | February 20, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circoutcomes.125.012622 | PMID 41717695 Get It

BACKGROUND: While health systems have implemented resources to improve lipid management in people with atherosclerotic cardiovascular disease, the population-level effectiveness is unclear. METHODS: Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, across 16 US academic health systems were analyzed. Atherosclerotic cardiovascular disease (defined by diagnosis and procedure codes) was established on or before the index date defined as the date of the most recent LDL-C (low-density lipoprotein-cholesterol) or the last day of the study period for those without an LDL-C available. Systems were surveyed to identify lipid management programs (eg, prevention/lipid clinic, electronic health record–based tools, and lipid management algorithms). Sequential multilevel multivariable logistic regression modeling was used to (1) assess the system-level association between an LDL-C <70 mg/dL and the presence of lipid management programs, adjusting for patient-level demographic and clinical characteristics, and (2) whether system-level uptake of statin or nonstatin lipid-lowering therapy was associated with an LDL-C <70 mg/dL. RESULTS: We included 1 738 042 patients with atherosclerotic cardiovascular disease (median, 88 365 per system; range, 17 086–2 48 371). About 81% of the health systems had prevention or lipid clinics. The proportion of those on statins ranged from 31.0% to 60.4% across health systems (median, 46.3%). Lower proportions were observed in the use of high-intensity statins (16.2%–33.1%), nonstatins (2.6%–8.1%), and combination lipid-lowering therapy (1.7%–6.3%). Among those with an LDL-C level available (n=890 521), 42.5% had an LDL-C <70 mg/dL, ranging 35.8% to 49.4% across systems. There was no association between the odds of achieving LDL-C <70 mg/dL and health system lipid management algorithm, prevention clinics/lipid clinics, or electronic health record–based tools. Neither system-level high-intensity statin utilization nor nonstatin use was associated with an LDL-C <70 mg/dL. CONCLUSIONS: Despite variability in lipid management resources and lipid-lowering therapy use across systems, many did not reach an LDL-C <70 mg/dL, and there was low uptake of lipid-lowering therapy. Innovative implementation strategies are needed for system-level lipid management.
Immunotherapy in Synchronous Gastric and Colonic Deficient Mismatch Repair Malignancies in a Case Series of Patients With Lynch Syndrome
Chung, Kevin , Schwengber, Wallace Klein , Shah, Surbhi, Wasif, Nabil , Samadder, Jewel J., Zhu, Mojun , Wu, Christina, Wu, Christina , Schwengber, Wallace Klein , Samadder, N Jewel , Wu, Christina

Mayo Clinic

JCO Precision Oncology | February 19, 2026 | Volume: 10 | Issue: 2 | Pages: No page available

10.1200/po-25-00433 | PMID 41712873 Get It

Circulating Tumor DNA and Blood-Based Biomarkers for Predicting Cardiotoxicity in Cancer Therapy: Toward Precision Cardio-Oncology
Thukral, Jatin, Moudgil, Pyush, Moudgil, Navish, Sindhwani, Ninaad, Dhawan, Ashish, Shah, Riya Kaushal, Kaur, Harbir, Thukral, Nikhil, Chandani, Kanishka Uttam, Agrawal, Siddharth Pravin, Frishman, William H., Aronow, Wilbert S., Thukral, Jatin, Kaur, Harbir, Thukral, Nikhil, Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001205 | PMID 41711464 Get It

Advances in cancer therapeutics have substantially improved survival across multiple malignancies but have concurrently increased the burden of cancer therapy–related cardiovascular toxicity, establishing cardio-oncology as an essential discipline situated at the interface of oncology and cardiovascular medicine. Despite growing incorporation of cardiac imaging and circulating cardiac biomarkers into surveillance strategies, current approaches remain limited by modest specificity, heterogeneous risk profiles, and inconsistent translation into effective cardioprotective interventions. This review synthesizes contemporary evidence on the biological mechanisms underlying cancer therapy–related cardiovascular toxicity and critically evaluates the current role and limitations of established cardiac biomarkers, including high-sensitivity cardiac troponins and natriuretic peptides, in risk stratification and early injury detection. We further examine why many cardioprotective clinical trials have yielded neutral or modest results, highlighting signal dilution arising from low-risk populations, endpoint heterogeneity, and timing mismatches between injury biology and intervention. This review advances a precision cardio-oncology framework by integrating tumor-derived liquid biopsy platforms—such as circulating tumor DNA, tissue-specific cell-free DNA, and extracellular vesicles—with cardiac biomarkers to provide a biologically contextualized assessment of cardiovascular risk. Tumor-derived biomarkers may reflect treatment intensity, systemic inflammatory burden, and cardiotoxic susceptibility, thereby enhancing the interpretation of cardiac biomarker signals and refining patient selection for targeted cardioprotective strategies.
CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link?
Gava, Flavia , Yates, Bonnie , Sun, Zhouxin, Li, Grace , O'Koren, Chelsea, Adhikari, Biplov , Luger, S. M., Shalabi, Haneen , Mattison, Ryan J. , Türkbey, Evrim , Paietta, Elisabeth , Wang, Hao-Wei, Mullighan, Charles G., Litzow, M., Shah, Nirali N, Turkbey, Evrim B , Yuan, Constance M , Wang, Hao-Wei , Mullighan, Charles G , Litzow, Mark R. , Shah, Nirali N , Yuan, Constance M. , Wang, Hao‐Wei , Mullighan, Charles G. , Silbert, Sara K. , Litzow, Mark R.

Mayo Clinic

Blood Advances | February 18, 2026 | Volume: 10 | Issue: 9 | Pages: 3044-3053

10.1182/bloodadvances.2025018480 | PMID 41707115 Get It

Abstract Cytokine receptor–like factor 2 rearrangement (CRLF2r), an aberration causing a Philadelphia chromosome–like gene expression profile and a poor prognostic marker in B-cell acute lymphoblastic leukemia (B-ALL), endows relative chemotherapeutic resistance. Extramedullary disease (EMD), including both central nervous system (CNS) and non-CNS involvement, can also be associated with worse outcomes. The relationship between CRLF2r and EMD is unknown. Based on an initial observation of patients with relapsed/refractory (R/R) CRLF2r B-ALL and EMD, a single-center retrospective review was conducted to evaluate the incidence of EMD in patients with CRLF2r B-ALL. Across 177 children, adolescents, and young adults with R/R B-ALL, 21 (11.9%) harbored CRLF2r, of whom 19 (90.5%) had EMD at some point during their treatment course. In contrast, only 78 of the 156 patients (50%) without CRLF2r ever had EMD (P = .0003). In the CRLF2r cohort, 8 (38.1%) presented with EMD at diagnosis: 7 with CNS and 1 with non-CNS EMD. At relapse, 17 (80.9%) had EMD: 4 (19%) had CNS EMD, 9 (42.9%) had non-CNS EMD, and 4 (19%) had both. Isolated EMD was observed in 2 patients (11.8%) at first relapse and in 3 (17.6%) with multiple relapses. Given these findings, further study to evaluate this potential association between EMD and CRLF2r in R/R B-ALL is indicated.
Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study
Ruan, Jia , Chen, Zhengming , Larson, Melissa C, Bennani, N Nora, Allen, Pamela B. , Mou, Eric , Wallace, Danielle , Mehta-Shah, Neha, Lossos, Izidore S, Castillo, Luis E Malpica, Vega, Francisco, Inghirami, Giorgio GA, Pongas, Georgios , Akkad, Neha, Casulo, C., Martin, Peter, Cohen, Jonathon B. , Habermann, Thomas M, Maurer, Matthew J., Leonard, John P, Friedberg, Jonathan W. , Cerhan, James R, Flowers, Christopher R, Feldman, Andrew L, Bennani, N. Nora , Chen, Zhengming , Malpica, Luis , Bennani, N Nora , Allen, Pamela Blair , Mehta-Shah, Neha , Lossos, Izidore S , Malpica Castillo, Luis E , Vega, Francisco , Inghirami, Giorgio , Casulo, Carla , Cohen, Jonathon B , Maurer, Matthew , Kahl, Brad S , Cerhan, James R , Flowers, Christopher R , Feldman, Andrew L , Mou, Eric , Wallace, Danielle S , Larson, Melissa C. , Mehta–Shah, Neha , Lossos, Izidore S. , Castillo, Luis Enrique Malpica , Jaye, David L. , Inghirami, Giorgio , Akkad, Neha , Casulo, Carla , Habermann, Thomas M. , Leonard, John P. , Kahl, Brad S. , Cerhan, James R. , Flowers, Christopher R. , Feldman, Andrew L.

Mayo Clinic

Blood Advances | February 18, 2026 | Volume: 10 | Issue: 10 | Pages: 3480-3493

10.1182/bloodadvances.2025018455 | PMID 41707114 Get It

Abstract Few prospective benchmark studies exist to characterize the evolving contemporary real-world practice for peripheral T-cell lymphoma (PTCL). We report the patterns of first-line care and outcomes for 720 patients with systemic PTCL enrolled in 2 related prospective cohort studies, Lymphoma Epidemiology of Outcomes (LEO) from 2015 to 2020 and Molecular Epidemiology Resource (MER) from 2002 to 2015, both followed to 2024. The primary end points were event-free survival (EFS) and overall survival (OS) using Kaplan-Meier estimator and Cox regression model. Secondary end points included correlations of clinical and treatment factors with survival. The most common induction regimens were CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) based (70%), given as CHOP (36%), CHOP plus etoposide (23%), or CHOP-like plus novel agents (11.5%, including 5% BV-CHP [brentuximab plus cyclophosphamide, doxorubicin, and prednisone]). Consolidative autologous stem cell transplant was performed in 102 patients (14%). Within nodal PTCL, EFS and OS were adversely associated with International Prognostic Index 2 to 5, prognostic index for T-cell lymphoma score 1 to 4, and non–anaplastic large-cell lymphoma (ALCL) subtypes. Within LEO, which captured increasing first-line etoposide and brentuximab vedotin, adding etoposide to CHOP was associated with better OS in anaplastic lymphoma kinase-negative ALCL. BV-CHP showed a trend toward OS improvement in ALCL. Patients failing EFS6 and EFS24 had 5-year subsequent OS of 12% and 17%, respectively. The inferior outcomes in non-ALCL subtypes and patients failing EFS6 and EFS24 highlight unmet needs with CHOP-based induction, where clinical trials with targeted therapy should be prioritized. This trial was registered at www.clinicaltrials.gov as NCT02736357.
Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence–driven oncology care
Emamekhoo, Hamid, Riaz, Irbaz, Martin, Daniel B., Gabriel, Peter E. , Bruckner, Lauren B. , Arafat, Waddah, Fu, Penelope, Liebovitz, David , Stillman, Robert C. , Stapp, Robert T, Perkins, Randa M., Sugalski, Jessica , Heinrichs, Tricia , Tevaarwerk, Amye J., Gabriel, Peter , Emamekhoo, Hamid , Emamekhoo, Hamid , Stillman, Robert C , Heinrichs, Tricia , Tevaarwerk, Amye J , Shah, Neil J , Arafat, Waddah , Freimuth, Robert R. , Stapp, Robert , Perkins, Randa, Tevaarwerk, Amyé

Mayo Clinic

Cancer | February 17, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70307 | PMID 41701629 Get It

Abstract The adoption of electronic health records (EHRs) has transformed health care, improving efficiency and chart accessibility. However, the widespread reliance on unstructured data entry and the lack of standardized documentation frameworks have resulted in significant data fragmentation across health care systems. The prevalence of unstructured data in EHRs limits their potential for clinical decision support, trial matching, real‐world evidence (RWE) generation, and quality measurement. Data fragmentation in health care triggers a cascade of challenges that ultimately compromise patient care. Clinicians face an excessive documentation burden and struggle to locate critical information buried in unstructured notes. Researchers encounter difficulties in extracting reliable clinical data. EHR vendors grapple with standardizing unstructured information for interoperability, and payers are unable to process unstructured clinical data efficiently to support value‐based care models. These challenges are particularly acute in oncology, where complex clinical elements like cancer staging, disease status, and treatment changes require precise, structured documentation. Emerging artificial intelligence (AI) technologies, such as large language models (LLMs) and ambient listening, offer a path to automate structured data generation while reducing the workload on providers. Here, the authors propose LLM‐based workflows that balance automation with clinician verification, streamlining data entry without compromising accuracy. Realizing these benefits requires coordinated efforts among clinicians, researchers, EHR vendors, payers, and policymakers to align regulatory frameworks with AI‐driven innovations. This article outlines a strategy to enhance structured data capture within EHRs, ultimately improving patient care, research, and health care efficiency.